GlassScriptPhysician profile
Shreemayee De
NPI 1962812875
$3,051.93
in general payments reported to CMS, 2019-2025
29 companies · $825 in 2025
The $825 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.18 · 2020: $58.58 · 2021: $265 · 2022: $315 · 2023: $373 · 2024: $1,152 · 2025: $825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,201 · Travel and Lodging: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,200.99 |
| Travel and Lodging | $149.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $367.82 | 2021-2025 | Farxiga, Lokelma |
| Amgen INC. | $301.35 | 2021-2025 | Tavneos, Uplizna, Repatha |
| Nxstage Medical, INC. | $291.54 | 2022-2025 | Nxstage System One |
| Vifor Pharma, INC. | $282.50 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $276.19 | 2023-2025 | |
| Abbott Laboratories | $211.17 | 2023-2024 | Freestyle Libre 3 |
| Calliditas Therapeutics US INC. | $158.85 | 2025 | Tarpeyo |
| Daxor Corporation | $127.65 | 2024 | Bva-100 |
| Lilly USA, LLC | $112.24 | 2024-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $103.21 | 2023-2025 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $101.29 | 2023-2025 | Heplisav-B |
| Bayer Healthcare Pharmaceuticals INC. | $91.48 | 2024-2025 | |
| Novo Nordisk INC | $85.28 | 2023-2024 | Rybelsus, Ozempic |
| Alexion Pharmaceuticals, INC. | $77.45 | 2024 | Ultomiris |
| Fresenius USA Marketing, INC. | $72.82 | 2019-2023 | Velphoro |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $65.33 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $55.21 | 2019-2021 | |
| Cycle Pharmaceuticals INC | $49.80 | 2024-2025 | Tiopronin, Venxxiva |
| Corcept Therapeutics | $38.93 | 2025 | Korlym |
| Aurinia Pharma U.S., INC. | $32.66 | 2024-2025 | Lupkynis |
| Gilead Sciences, INC. | $22.79 | 2023 | Epclusa |
| Optinose US, INC. | $21.50 | 2025 | |
| Kyowa Kirin, INC. | $16.15 | 2024 | Crysvita |
| Inspire Medical Systems, INC. | $15.78 | 2025 | Inspire |
| Akebia Therapeutics INC | $15.41 | 2021 | |
| Genzyme Corporation | $14.94 | 2019 | |
| Xeris Pharmaceuticals, INC. | $14.35 | 2023 | Keveyis |
| Daiichi Sankyo INC. | $14.21 | 2021 | |
| Mallinckrodt Hospital Products INC. | $14.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shreemayee De listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.